MedTrace Logo

A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

NCT05031494 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-01-06

No results posted yet for this study

Summary

A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC)

Conditions

Interventions

DRUG

YH003

YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.

DRUG

Toripalimab

Toripalimab will be administered at a dose of 240 mg every 3 weeks.

DRUG

Nab-paclitaxel

Nab-paclitaxel will be administered each 21-day cycle.

DRUG

Gemcitabine

Gemcitabine will be administrated each 21-day cycle.

Sponsors & Collaborators

  • Eucure (Beijing) Biopharma Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-08
Primary Completion
2023-08-16
Completion
2023-08-16
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05031494 on ClinicalTrials.gov